article_snippet: The Food and Drug Administration is keeping a bold-letter warning on Pfizer's anti-smoking drug Chantix about suicidal behavior and other psychiatric side effects, after reviewing company findings suggesting Drug does not increase those problems.
article_snippet: The FDA The FDA on Monday outlined several updates to Chantix's labeling, including a new warning about The FDA potential interaction with alcohol.
article_snippet: Chantix has carried the FDA's strongest warning label since 2009, following reports of suicidal tendencies and violent or bizarre behavior among some patients . '
article_snippet: We have approved changes to the Chantix label to warn about these risks.
article_snippet: The updated labeling also includes information from several studies and analyses conducted by Pfizer that found no difference in psychiatric problems between people taking Chantix and other stop-smoking treatments. '
article_snippet: several studies and analyses conducted by Pfizer that found no difference in psychiatric problems between people taking Chantix and other stop-smoking treatments did not show an increased risk of neuropsychiatric side effects with Chantix; however, several studies and analyses conducted by Pfizer that found no difference in psychiatric problems between people taking Chantix and other stop-smoking treatments did not examine all types of neuropsychiatric side effects, and several studies and analyses conducted by Pfizer that found no difference in psychiatric problems between people taking Chantix and other stop-smoking treatments had limitations that prevented us from drawing reliable conclusions,' the FDA said.
article_snippet: Last year Pfizer proposed that the FDA the FDA remove Chantix's so-called black box warning based on the company's findings and other data.
article_snippet: Warning: the FDA the FDA on Monday outlined several updates to Chantix's labeling, including a new warning about the FDA potential interaction with alcohol.
article_snippet: Pfizer is expected to complete a larger study of Chantix's psychiatric side effects in late 2015.
article_snippet: Chantix's safety has been debated in medical journals and courtrooms since 2007, when reports of suicide, agitation and other problems first began streaming into the FDA.
article_snippet: the drug's labeling currently tells patients to stop taking Chantix immediately if patients experience agitation, depressed mood, suicidal thinking and other behavioral changes.
highlights_snippet: The FDA is keeping a bold-letter warning on Pfizer's anti-smoking drug Chantix about suicidal behavior and other psychiatric side effects .
  
highlights_snippet: The FDA The FDA on Monday outlined several updates to Chantix's labeling, including a new warning about The FDA potential interaction with alcohol .
  